Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center

被引:0
作者
Botella, Carmen [1 ]
Galian, Jose Antonio [1 ]
Jimenez-Coll, Victor [1 ]
Fernandez-Gonzalez, Marina [1 ]
Morales, Francisco [2 ]
Martinez-Gomez, Gloria [3 ]
Gonzalez-Lopez, Rosana [1 ]
Alegria, Maria Jose [1 ]
Moya, Maria Rosa [1 ]
Martinez-Banaclocha, Helios [1 ]
Minguela, Alfredo [1 ]
Legaz, Isabel [4 ]
Llorente, Santiago [2 ]
Muro, Manuel [1 ]
机构
[1] Univ Clin Hosp Virgen Arrixaca, Biomed Res Inst Murcia IMIB, Immunol Serv, Murcia 30120, Spain
[2] Univ Clin Hosp Virgen Arrixaca, Biomed Res Inst Murcia IMIB, Nephrol Serv, Murcia 30120, Spain
[3] Univ Clin Hosp Virgen Arrixaca, Biomed Res Inst Murcia IMIB, Urol Serv, Murcia 30120, Spain
[4] Univ Murcia, Biomed Res Inst Murcia IMIB, Fac Med, Dept Legal & Forens Med,Reg Campus Int Excellence, Murcia 30100, Spain
来源
LIFE-BASEL | 2024年 / 14卷 / 11期
关键词
donor-derived circulating free DNA (dd-cfDNA); kidney transplant; graft rejection; biomarker; non-rejection (NR); antibody-mediated rejection (ABMR); borderline rejection (BR); T-cell-mediated rejection (TCMR); TRANSPLANTATION; REJECTION;
D O I
10.3390/life14111491
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
(1) Background: donor-derived circulating free DNA (dd-cfDNA), an innovative biomarker with great potential for the early identification and prevention of graft damage. (2) Methods: Samples were collected prospectively and the study was performed retrospectively to analyze dd-cfDNA plasma levels in 30 kidney transplant patients during their post-transplant follow-up (15 days, 3, 6, and 9 months), to determine if the result could be of interest in the identification of possible adverse events, especially rejection. The aim was to verify whether the data on sensitivity, specificity, NPV, and PPV compare with reference values and creatinine values. (3) Results: We observed levels of dd cfDNA > 1% in six of nine patients with active rejection (ABMR or TCMR) and elevated values (>0.5%) in two other patients in this rejection group. Our results show low values of sensitivity = 50%, specificity = 61.11%, rejection NPV = 64.71%, and rejection PPV = 46.13% of the technique compared to reference values previously published. With respect to creatinine, only for TCRM, we observed better results for dd-cfDNA in these parameters than in creatinine. Also, our data suggest that dd-cfDNA could help to differentiate those patients with dnDSAs that are going to through rejection better than creatinine, specially at 15 d post transplant. In this study, this appears to have no positive predictive value for borderline rejection (BR) or TCMR IA. (4) Conclusions: plasma levels of dd-cfDNA could be considered an additional or alternative biomarker for graft rejection monitoring in early post-kidney transplant up to several months before its clinical presentation, especially for patients with suspected TCMR or ABMR.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Donor-derived cell-free DNA for detection of acute rejection in lung transplant recipients
    Yavuz, Goekce
    Walter, Julia
    Hirv, Kaimo
    Wachter, Oliver
    Dick, Andrea
    Kovacs, Julia
    Zimmermann, Julia
    Glueck, Olaf M.
    Vorstandlechner, Maximilian
    Samm, Nicole
    Fertmann, Jan M.
    Sienel, Wulf
    Michel, Sebastian
    Irlbeck, Michael
    Kneidinger, Nikolaus
    Hatz, Rudolf
    Behr, Juergen
    Schneider, Christian
    Kauke, Teresa
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [22] Lack of Usefulness of Donor-Derived Cell-Free DNA as a Biomarker for Cardiac Allograft Vasculopathy: A Prospective Study
    Bravo, Marta Jimenez-Blanco
    Perez-Gomez, Laura
    Hernandez-Perez, Francisco J.
    Arellano-Serrano, Carlos
    Torres-Sanabria, Mario
    Gomez-Bueno, Manuel
    Oteo-Dominguez, Juan F.
    Mingo-Santos, Susana
    Segovia-Cubero, Javier
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [23] Donor-derived cell-free DNA and renal allograft rejection in surveillance biopsies and indication biopsies
    Chang, Jae-Hyung
    Verduzco, Hector Alvarado
    Toma, Katherine
    Sritharan, Sharlinee
    Mohan, Sumit
    Husain, Syed Ali
    CLINICAL TRANSPLANTATION, 2022, 36 (04)
  • [24] Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation
    Agbor-Enoh, Sean
    Wang, Yan
    Tunc, Ilker
    Jang, Moon Kyoo
    Davis, Andrew
    De Vlaminck, Iwijn
    Luikart, Helen
    Shah, Pali D.
    Timofte, Irina
    Brown, Anne W.
    Marishta, Argit
    Bhatti, Kenneth
    Gorham, Sasha
    Fideli, Ulgen
    Wylie, Jennifer
    Grimm, David
    Goodwin, Natalie
    Yang, Yanqin
    Patel, Kapil
    Zhu, Jun
    Laconoad, Aldo
    Orens, Jonathan B.
    Nathan, Steven D.
    Marboe, Charles
    Berry, Gerald J.
    Quake, Stephen R.
    Khush, Kiran
    Valantine, Hannah A.
    EBIOMEDICINE, 2019, 40 : 541 - 553
  • [25] Donor-Derived Cell-Free DNA in Kidney Transplantation: Origins, Present and a Look to the Future
    Kant, Sam
    Brennan, Daniel C.
    MEDICINA-LITHUANIA, 2021, 57 (05):
  • [26] Remote monitoring using donor-derived, cell-free DNA after kidney transplantation during the coronavirus disease 2019 pandemic
    Potter, Steven R.
    Hinojosa, Randall
    Miles, Cliff D.
    O'Brien, Dan
    Ross, David J.
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2020, 39 (04) : 495 - 500
  • [27] Reduction in Maintenance Immunosuppression in Kidney Transplant Recipients With Stable Donor-Derived Cell-Free DNA Measurements: A Case Series
    Lum, Erik L.
    Towns, Arta
    Basuli, Debargha
    Pham, Phuong-Thu
    Sarkar, Mrinalini
    Bunnapradist, Suphamai
    TRANSPLANTATION PROCEEDINGS, 2023, 55 (01) : 93 - 97
  • [28] Combined Metagenomic Viral Detection and Donor-Derived Cell-Free DNA Quantification in Plasma From Kidney Transplant Recipients
    Sinha, Rohita
    Zhu, Zixuan
    Park, Sookhyeon
    Rebello, Christabel
    Kinsella, Bradley
    Friedewald, John
    Kleiboeker, Steven
    TRANSPLANTATION PROCEEDINGS, 2024, 56 (06) : 1522 - 1530
  • [29] Use of a donor-derived cell-free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection
    Steggerda, Justin A.
    Pizzo, Helen
    Garrison, Jonathan
    Zhang, Xiaohai
    Haas, Mark
    Kim, Irene K.
    Jordan, Stanley C.
    Puliyanda, Dechu P.
    PEDIATRIC TRANSPLANTATION, 2022, 26 (04)
  • [30] Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial
    Akifova, Aylin
    Budde, Klemens
    Amann, Kerstin
    Buettner-Herold, Maike
    Choi, Mira
    Oellerich, Michael
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Schuetz, Ekkehard
    Bachmann, Friederike
    Halleck, Fabian
    von Hoerschelmann, Ellen
    Koch, Nadine
    Schrezenmeier, Eva
    Seelow, Evelyn
    Waiser, Johannes
    Zukunft, Bianca
    Eckardt, Kai-Uwe
    Halbritter, Jan
    Kettritz, Ralph
    Del Moral, Covadonga Lopez
    Lachmann, Nils
    Stauch, Diana
    Niemann, Matthias
    Schmidt, Danilo
    Halloran, Philip F.
    Osmanodja, Bilgin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2025,